18/04/2019 19:02:31

APR 26 DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO

NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AVEO investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2019.

To join the AVEO class action, go to https://pawarlawgroup.com/cases/aveo-pharmaceuticals-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the TIVO-3 trial was inadequately designed to address the overall survival concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented back in the June 2013; (2) tivozanib had insufficient survival data to obtain U.S. Food and Drug Administration (“FDA”) approval following its initial rejection by the FDA in 2013; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://pawarlawgroup.com/cases/aveo-pharmaceuticals-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar, Esq. of Pawar Law Group toll free at 888-589-9804 or via e-mail at info@pawarlawgroup.com.

No class has been certified.  Until a class is certified, you are not represented by counsel unless you hire one.  You may hire counsel of your choice.  You may also do nothing at this time and be an absent member of the class.  Your ability to share in any future recovery is not dependent upon being a lead plaintiff. 

Pawar Law Group represents investors from around the world. Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact:  

Vik Pawar, Esq.  

Pawar Law Group  

20 Vesey Street, Suite 1210  

New York, NY 10007  

Tel: (917) 261-2277  

Fax: (212) 571-0938  

info@pawarlawgroup.com  

Pawar-Law-Group-logo-gold.png

Related content
26 Apr - 
APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announce..
25 Apr - 
CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi ..
25 Apr - 
FRIDAY DEADLINE: The Schall Law Firm Announces the Fili..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
2
MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations
3
Bone Therapeutics SA to report half year 2019 results on 30 August 2019
4
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
5
Ambu A/S: Interim report for Q3 2018/19

Related stock quotes

Aveo Pharmaceuticals Inc 0.6945 2.4% Stock price increasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 08:49:37
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB3 - 2019-08-22 09:49:37 - 2019-08-22 08:49:37 - 1000 - Website: OKAY